An interventional study of 360º goniotomy assisted transluminal trabeculotomy and Phacoemulsification in Open Angle Glaucoma (OAG), sponsored by Faculdade de Ciências Médicas de Minas Gerais. Recruiting at 1 site in Brazil. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.
Sponsored by Faculdade de Ciências Médicas de Minas Gerais · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Glaucoma, Open-Angle with a site in Brazil — 1 open to participants now, 1 under way, none of them phase 3. Glaucoma, Open-Angle · Brazil.
Among the 18 studies in Glaucoma, Open-Angle with a site in Brazil, this one is the 7th largest by planned enrollment, is the only one that started in 2024, is one of 5 with no phase, and was the 18th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 18 studies in Glaucoma, Open-Angle with a site in Brazil is open now.
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 6 · Phase 4 4
First in 2006; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 55 across the 18 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
Faculdade de Ciências Médicas de Minas Gerais is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Faculdade de Ciências Médicas de Minas Gerais has 1 study filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Glaucoma, Open-Angle with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospective, randomized, , double-blind, clinical trial, comparing the variation of intraocular pressure (IOP) of patients with mild or moderate primary open-angle glaucoma (OAG) and cataract divided into three groups. All study participants should be treated for the pathology with one or more hypotensive medications or, regardless of the number of drugs, when IOP is greater than 20 mmHg and less than 26 mmHg. The two-year follow-up should also compare the reduction in the number of medications used, reoperation rate, adverse effects, visual acuity, endothelial loss, induction of astigmatism, variation in IOP according to axial diameter of the eye, anterior chamber and age, in addition to the existence of change in the quality of life of patients in the postoperative period
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who have any of the following situations:
Procedure: 360º goniotomy assisted transluminal trabeculotomy · Procedure: Phacoemulsification
Procedure: Phacoemulsification · Procedure: 180º gonioscopy assisted transluminal trabeculotomy
Control Group
Procedure: Phacoemulsification
Open the Schlemm Canal for 360º with a polipropilen 5-0 suture via trabecular meshwork.
Cataract Surgery
Open the Schlemm Canal for 180º with a polipropilen 5-0 suture via trabecular meshwork.
Also known as: 180º GATT, Hemi - GATT
Change in intraocular pressure (IOP) after surgery.
To evaluate the change in intraocular pressure (IOP) after surgery, in patients with mild to moderate GPAA, undergoing phacoemulsification associated with gonioscopy assisted transluminal trabeculotomy by 180º (GATT 180º) or 360º (GATT 360º), and compare the results between the groups mentioned and with similar controls, who operated only on cataracts, in a period of up to two years.
Time frame: From glaucoma medications washout to 2 years after the surgery
Change in the number of glaucoma medications after surgery.
To evaluate the change in the number of glaucoma medications applied after surgery, in patients with mild to moderate GPAA, undergoing phacoemulsification associated with gonioscopy assisted transluminal trabeculotomy by 180º (GATT 180º) or 360º (GATT 360º), and compare the results between the groups mentioned and with similar controls, who operated only on cataracts, in a period of up to two years.
Time frame: From glaucoma medications washout to 2 years after the surgery
Prognostic factors of the surgeries.
Evaluate the association of IOP variation with axial eye length (AXL) in the groups.
Time frame: From glaucoma medications washout to 2 years after the surgery
Prognostic factors of the surgeries.
Evaluate the association of IOP variation with preoperative anterior chamber amplitude (ACD) in the groups.
Time frame: From glaucoma medications washout to 2 years after the surgery
Prognostic factors of the surgeries.
Evaluate the association of IOP variation with age in the groups
Time frame: From glaucoma medications washout to 2 years after the surgery
Survival Analysis
Evaluate and compare the need for new glaucoma surgeries between the groups.
Time frame: From glaucoma medications washout to 2 years after the surgery
Secundary changes in the eye after the surgeries
Evaluate the visual acuity after the surgeries and compare between them.
Time frame: From glaucoma medications washout to 2 years after the surgery
Secundary changes in the eye after the surgeries
Evaluate and compare the adverse events after the surgeries.
Time frame: From glaucoma medications washout to 2 years after the surgery
Secundary changes in the eye after the surgeries
Evaluate the decrease in corneal endothelial cell count between the groups.
Time frame: From glaucoma medications washout to 2 years after the surgery
Prognostic factors, and secundary changes in the eye after the surgeries
Evaluate and compare the change in quality of life in and between the groups.
Time frame: From glaucoma medications washout to 2 years after the surgery
Secundary changes in the eye after the surgeries
Evaluate the induction of astigmatism between the groups
Time frame: From glaucoma medications washout to 2 years after the surgery
Plan to share: Yes — all IPD collected throughout the trial
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Feb 2028, 45 months after the start.
Of 101 non-industry interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 45 months is above that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Faculdade de Ciências Médicas de Minas Gerais